CHAPEL HILL, NC, (http://www.financialnewsmedia.com News Alert) -- Crown Marketing (OTCQB: CWNM) is pleased to announce that patents for its Controlled Drug Delivery Technology (CDDT) have been approved and registered in Mexico.
Stay informed on Crown Marketing developments by getting FREE news alerts & updates delivered directly to your mobile phone by texting STOCK to 545454 from your cellular device or visit http://cwnm.mobi for more details.
Mexico\'s pharmaceutical industry faces unique challenges. According to an American Enterprise Institute study, Mexico\'s $15.5 billion market is plagued by counterfeit goods. Illicit activity in Mexico\'s pharmaceutical industry is estimated at roughly USD 1.9 billion per year -- with counterfeiting representing 81 percent of that illicit market. This is a situation where Crown believes its unique technology could have a significant impact.
In addition to protecting Crown\'s interest in Mexico\'s burgeoning market, Crown believes that its drug delivery device would significantly inhibit the ability to counterfeit medications due to its unique form and process of manufacture.
The intellectual property supporting the Controlled Drug Delivery Technology (CDDT) is comprehensively formulated to allow for the broad application of the technology with regard to the mode of administration, the desired release pattern, the type of compounds employed and the dosage form.
The technology can be employed to regulate time to first release of drug, the extent of the initial bolus release and the duration of the remaining controlled release. These programmable release profiles may be adjusted for considerations given to the different gastric and intestinal environments.
Crown\'s patent portfolio continues to increase as it is pursuing novel applications of its drug delivery technology.
About The Company:
Crown Marketing Crown\'s Controlled Drug Delivery Technology (CDDT) is a novel controlled-release technology, harnessing the principles diffusion through precise mathematical formulas. The spectrum and reliability of pharmacokinetic profiles achievable with this technology is superior to currently marketed...